# Curaleaf Laboratories becomes first UK manufacturer of medical cannabis suppositories > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/curaleaf-laboratories-becomes-first-uk-manufacturer-of-medical-cannabis-suppositories/ > **Published:** 2026-05-12T10:19:52-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:55:34-04:00 > **Clinical Summary:** Cannabis suppository bioavailability offers improved dosing through rectal delivery, bypassing first-pass metabolism. Clinical guide for clinicians. --- ✦ New CED Clinical Relevance #45 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. ResearchIndustryDosingSafety Why This Matters The availability of cannabis suppositories represents a clinically relevant alternative delivery method that may improve patient tolerability and bypass hepatic first-pass metabolism, potentially offering more consistent dosing for patients who cannot tolerate smoking or oral administration. This development is significant for clinicians treating patients with conditions like inflammatory bowel disease, [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), or nausea where rectal delivery could enhance therapeutic efficacy and reduce gastrointestinal side effects. As the UK [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) market expands with new formulations, clinicians should familiarize themselves with the pharmacokinetic properties of suppository delivery to optimize dosing and counsel patients appropriately on this emerging option. Clinical Summary Curaleaf Laboratories has become the first authorized manufacturer of [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) suppositories in the United Kingdom, expanding the available delivery methods for patients requiring cannabis-based medicines. Suppository formulations offer potential clinical advantages over oral and inhaled routes, including bypassed first-pass hepatic metabolism, improved bioavailability for certain cannabinoids, and reduced systemic side effects, which aligns with growing international evidence supporting alternative delivery systems. This development increases treatment options for patients with specific medical conditions such as inflammatory bowel disease, [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), or those unable to tolerate oral medications, while also supporting the UK’s evolving regulatory framework for medicinal cannabis. The availability of pharmaceutical-grade suppositories manufactured under standardized conditions addresses previous concerns about product consistency and quality in cannabis-based medicines. Clinicians should consider suppository formulations as an additional option when evaluating [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) for eligible patients, particularly those seeking alternatives to smoking or oral administration, and should remain informed about emerging delivery methods as the medical cannabis market continues to mature. Dr. Caplan’s Take “Suppository delivery is clinically significant because it bypasses first-pass hepatic metabolism, allowing us to achieve therapeutic cannabinoid levels with lower doses and more predictable pharmacokinetics than oral administration, which matters particularly for patients with gastrointestinal dysfunction or those seeking to minimize systemic side effects.” Clinical Perspective The emergence of cannabis suppositories as a manufactured product in the UK reflects broader efforts to diversify cannabinoid delivery methods beyond smoking and oral forms, potentially offering advantages for patients with swallowing difficulties, nausea, or those seeking localized effects. While rectal delivery may enhance bioavailability for certain cannabinoids and reduce first-pass hepatic metabolism compared to oral dosing, clinicians should recognize that evidence supporting suppository formulations remains limited relative to other routes, and standardization of dose, onset time, and local tissue effects requires further investigation. The regulatory advancement is encouraging for patients who might benefit from alternative delivery systems, yet prescribers should remain cautious about claims of superiority until robust pharmacokinetic and clinical efficacy data emerge specifically for this formulation. Practical guidance for now involves discussing suppository options with eligible patients as a potential alternative when conventional cannabis products are unsuitable, while maintaining realistic expectations about efficacy 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Curaleaf%20Laboratories%20becomes%20first%20UK%20manufacturer%20of%20medical%20cannabis%20suppositories%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52376)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52376)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Curaleaf%20Laboratories%20becomes%20first%20UK%20manufacturer%20of%20medical%20cannabis%20suppositories%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D52376)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.mmjdaily.com/article/9836784/curaleaf-laboratories-becomes-first-uk-manufacturer-of-medical-cannabis-suppositories/](https://www.mmjdaily.com/article/9836784/curaleaf-laboratories-becomes-first-uk-manufacturer-of-medical-cannabis-suppositories/) Further Reading Evidence Watch[Long-Term Cannabis Therapy May Change MS Spasticity Outcomes](https://cedclinic.com/cannabis-for-ms-spasticity-meta-analysis-2026/) Research Digest[Research Digest: 20 Recent Studies – May 02, 2026](https://cedclinic.com/cannabinoid-based-interventions-autism-safety-effectiveness-2026/) CED Clinic Blog[When Ketogenic Diet Therapy Is Added After CBD](https://cedclinic.com/cbd-ketogenic-diet-epilepsy/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).